U.T. SOUTHWESTERN ADULT AIDS CLINICAL TRIALS UNIT

UT

• 批准号: 6626364
• 负责人: DAVID M. MARGOLIS
• 金额: $ 138.08万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6626364
• 关键词: AIDS; AIDS /HIV neuropathy; AIDS related neoplasm /cancer; AIDS therapy; HIV infections; Histoplasma; Mycobacterium avium; Mycobacterium tuberculosis; Pneumocystis pneumonia; antiAIDS agent; antiviral antibody; body composition; cardiovascular disorder; cardiovascular disorder prevention; clinical research; clinical trial phase I; cooperative study; cytomegalovirus; drug adverse effect; drug interactions; experimental designs; gender difference; glucose metabolism; hepatitis B virus group; hepatitis C virus; human immunodeficiency virus 1; human subject; human therapy evaluation; hydroxyurea; immunoregulation; immunotherapy; latent virus infection; lipid metabolism; longitudinal human study; nucleoside analog; nucleotide analog; nutrition; opportunistic infections; outcomes research; pathologic process; pharmacokinetics; prodrugs; protease inhibitor; statistics /biometry; therapy compliance

DESCRIPTION (adapted from applicant's abstract): The scientific focus of the University of Texas Southwestern Medical Center AIDS Clinical Trials Unit (UTSMC ACTU) will be on the immunopathogenesis of HIV infection and immune reconstitution of patients treated with HAART. Specific areas of expertise include the role of the adult thymus in immune reconstitution of patients on HAART, the role of HIV-specific CD4+ and CD8+ T cell responses in the control of HIV replication in patients who are, and are not, treated for HIV infection, and the role of immune activation in HIV immunopathogenesis. In addition, investigators at UTSMC ACTU have extensive expertise in lipodystrophies, which they will bring to the study of protease inhibitor-induced lipodystrophy. Given the strengths in both clinical and basic science, they feel that the proposed UTSMC ACTU will serve as an integral part of the AACTG's mission to develop novel and effective treatments for HIV infection through a better understanding of the mechanisms underlying the pathogenesis of HIV-induced illness. The overall goal of the UTSMC ACTU will be to contribute to the mission of the AACTG. This will involve the enrolling and retention of appropriate patients into clinical trials developed within the framework of the AACTG. These patients will include all members of the diverse population served by the clinical facilities. More importantly, they envision being active participants in the scientific research agenda of the AACTG, and will contribute substantially to its knowledge base and future direction. In order to complete this goal, the specific aims of the UTSMC ACTU will be: (1) to contribute to the HIV disease research agenda; (2) to contribute to the complications of HIV disease research agenda; (3) to contribute to the immunology research agenda; and (4) to contribute to other research agendas.

描述（改编自申请人的摘要）： 德克萨斯大学西南医学中心艾滋病临床试验部门 （UTSMC ACTU）将对HIV感染的免疫发病机制和免疫 用HAART治疗的患者的重建。 具体专门知识领域 包括成人胸腺在患者免疫重建中的作用， HAART，HIV特异性CD 4+和CD 8 + T细胞应答在对照中的作用 在接受和未接受艾滋病毒治疗的患者中， 感染，以及免疫激活在HIV免疫发病机制中的作用。 在 此外，UTSMC ACTU的研究人员在以下方面拥有广泛的专业知识： 脂肪营养不良，他们将带来的蛋白酶的研究 肥胖引起的脂肪营养不良 鉴于其在临床和 基础科学，他们认为，拟议UTSMC ACTU将作为一个 AACTG的使命是开发新颖有效的治疗方法， 通过更好地了解艾滋病毒感染的机制， 艾滋病毒引起的疾病的发病机制。 UTSMC ACTU的总体目标 将为AACTG的使命做出贡献。 这将涉及 制定临床试验招募和保留适当的患者 在AACTG的框架内。 这些患者将包括 临床设施所服务的不同人群。 更重要的是， 他们设想积极参与科学研究议程， AACTG，并将大大有助于其知识基础和未来 方向 为了完成这一目标，UTSMC的具体目标是 ACTU将：（1）促进艾滋病毒疾病研究议程;（2） 有助于艾滋病并发症的研究议程;（3） 有助于免疫学研究议程;（4）有助于其他 研究议程。